EL7.AI
StocksMediumUpdated•Originally published 8 September 2026•Updated 8 September 2026•
1 min read

Roivant Shares Surge 20% on Positive Phase 2 Results for PH-ILD Treatment

Key Facts

1Roivant announced positive Phase 2 PHocus trial results for mosliciguat in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD).
2The study results are being presented today at the European Respiratory Society (ERS) International Congress 2026.
3The company unveiled the ongoing Phase 3 PHrontier study as part of the drug's clinical development.

In a move reflecting advancements in the biotech sector's approach to rare diseases, Roivant announced positive Phase 2 results from its PHocus trial evaluating mosliciguat. The study targeted pulmonary hypertension associated with interstitial lung disease (PH-ILD), a life-threatening condition with significant unmet medical needs. According to reports, the findings are being presented today at the European Respiratory Society (ERS) International Congress 2026.

The clinical success provides critical context for the company's development pipeline, as Roivant unveiled the ongoing Phase 3 PHrontier study. Following the achievement of trial objectives in the PHocus study, the company and its subsidiary Pulmovant confirmed the progression to larger-scale testing. This transition to Phase 3 is considered a significant clinical milestone given the heterogeneity and severity of the disease being treated.

Market reaction was immediate, with ROIV shares surging approximately 20% in premarket trading as of September 8, 2026. Looking ahead, investors should monitor broader US economic catalysts today, including the JOLTs Job Openings and the ISM Manufacturing PMI, which may influence sector-wide volatility alongside the company's clinical momentum.